CONMED (NYSE:CNMD) Issues FY 2026 Earnings Guidance

CONMED (NYSE:CNMD) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 4.480-4.600 for the period, compared to the consensus estimate of 4.370. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

CONMED Trading Up 9.5%

Shares of NYSE:CNMD traded up $4.12 during midday trading on Thursday, hitting $47.33. The company had a trading volume of 536,116 shares, compared to its average volume of 558,335. The firm has a fifty day simple moving average of $36.89 and a 200 day simple moving average of $38.39. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of 26.95, a PEG ratio of 3.27 and a beta of 0.93. The company has a current ratio of 2.29, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85. CONMED has a 12 month low of $31.44 and a 12 month high of $56.63.

CONMED (NYSE:CNMD) last announced its quarterly earnings results on Wednesday, July 29th. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.28. CONMED had a return on equity of 13.84% and a net margin of 4.00%.The company had revenue of $343.49 million during the quarter, compared to analysts’ expectations of $337.60 million. During the same period in the prior year, the business posted $1.15 EPS. CONMED’s revenue was up .3% on a year-over-year basis. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. On average, analysts predict that CONMED will post 4.38 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CNMD. Piper Sandler restated a “neutral” rating and set a $45.00 price objective (up from $39.00) on shares of CONMED in a report on Thursday. Weiss Ratings reissued a “sell (d)” rating on shares of CONMED in a research report on Thursday, June 4th. Wells Fargo & Company upped their price target on CONMED from $39.00 to $46.00 and gave the stock an “equal weight” rating in a research report on Thursday. Zacks Research cut shares of CONMED from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Finally, Wall Street Zen raised shares of CONMED from a “hold” rating to a “buy” rating in a research note on Monday, July 20th. Five investment analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $41.40.

Trending Headlines about CONMED

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: CONMED reported second-quarter earnings of $1.38 per share, well above the $1.10 analyst consensus and up from $1.15 a year earlier. Revenue of $343.5 million also exceeded estimates of $337.6 million. CONMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 adjusted EPS guidance to $4.48-$4.60, above the prior analyst consensus of approximately $4.37. The updated outlook was a major positive catalyst for the stock. CONMED Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Management said sales rose 6.0% organically excluding the impact of previously announced strategic exits from certain gastrointestinal product offerings, suggesting healthier underlying demand than the headline revenue growth indicates. CONMED Second-Quarter Results and Guidance

Hedge Funds Weigh In On CONMED

A number of institutional investors have recently added to or reduced their stakes in CNMD. Invesco Ltd. raised its stake in CONMED by 29.9% in the fourth quarter. Invesco Ltd. now owns 184,070 shares of the company’s stock valued at $7,473,000 after purchasing an additional 42,395 shares in the last quarter. State of Tennessee Department of Treasury grew its holdings in shares of CONMED by 4.3% during the 4th quarter. State of Tennessee Department of Treasury now owns 21,139 shares of the company’s stock valued at $812,000 after purchasing an additional 873 shares during the last quarter. VARCOV Co. bought a new position in CONMED during the 4th quarter valued at approximately $1,007,000. Voloridge Investment Management LLC boosted its position in CONMED by 92.6% in the fourth quarter. Voloridge Investment Management LLC now owns 210,193 shares of the company’s stock worth $8,534,000 after purchasing an additional 101,052 shares during the last quarter. Finally, Susquehanna Portfolio Strategies LLC bought a new stake in shares of CONMED during the fourth quarter valued at approximately $1,517,000.

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.